Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Profit of Softline JSC in 2022 increased 6.7 times

4/12/23 SFTL

Government approves sale of Shell's stake in Sakhalin-2 to Novatek

4/12/23 NVTK

M.Video-Eldorado reduced debt by 35% in 2022

4/12/23 MVID

Samolet will participate in the development of 28.4 hectares in Eastern Biryuleyevo

4/12/23 SMLT

Italy allows Lukoil to sell ISAB

4/12/23 LKOH

VKontakte surpassed Telegram and YouTube by daily audience

4/12/23 VKCO

Procter & Gamble announced a quarterly dividend

4/11/23 PG

Pharmsintez reported for 2022 according to RAS

4/11/23 LIFE

Genetico will hold an IPO on the Moscow Exchange

4/11/23 GECO

Genetico's IPO offering price will be ₽17.88

4/11/23 ABIO